Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000000814
JPRN-UMIN000000814CompletedPhase 4

Effects of pioglitazone and metformin on mitochondrial function evaluated with 31P MRS in type 2 DM. - 31P MRS measurement of mitochondrial function and insulin resistance. (3M study)

Kobe University Hospital0 sites50 target enrollmentStarted: October 1, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 75years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1. Severe renal dysfunction(serum creatinine>2.0mg/dl) 2. Severe liver dysfunction(AST, ALT>50IU/ml) 3. Severe heart failure 4. History of hypersensitivity to pioglitazone or metformin 5. During the pregnancy or nursing 6. Arteriosclerosis obliterans (ASO) (ABI<0.9) 7. Poor control of plasma glucose (FPG>150mg/dl) 8. Inadequate to entry to this study

Investigators

Similar Trials

Completed
Not Applicable
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.diabetes mellitus II.non-insulin-dependent diabetes mellitus
IRCT201109067482N1Qazvin University of Medical Sciences40
Completed
Not Applicable
Effect of pioglitazone and metformin in combination with insulin therapy in patients with type 2 diabetesType 2 diabetes
JPRN-UMIN000003830Chigasaki Municipal Hospital250
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb Study
EUCTR2007-006706-14-ATTakeda Pharma GmbH200
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyDiabetes mellitus type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2007-006706-14-DETakeda Pharma GmbH
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetes
JPRN-UMIN000001891Jikei University School of Medicine20